Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

998 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Among authors: huang sm. Pharm Res. 2001 Aug;18(8):1071-80. doi: 10.1023/a:1010994022294. Pharm Res. 2001. PMID: 11587475 Review. No abstract available.
Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.
Vieira ML, Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, Huang SM. Vieira ML, et al. Among authors: huang sm. Clin Pharmacol Ther. 2012 Apr;91(4):700-8. doi: 10.1038/clpt.2011.305. Epub 2012 Mar 7. Clin Pharmacol Ther. 2012. PMID: 22398966
Transporter-mediated drug-drug interactions.
Zhang L, Huang SM, Lesko LJ. Zhang L, et al. Among authors: huang sm. Clin Pharmacol Ther. 2011 Apr;89(4):481-4. doi: 10.1038/clpt.2010.359. Clin Pharmacol Ther. 2011. PMID: 21423238
A regulatory viewpoint on transporter-based drug interactions.
Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. Zhang L, et al. Among authors: huang sm. Xenobiotica. 2008 Jul;38(7-8):709-24. doi: 10.1080/00498250802017715. Xenobiotica. 2008. PMID: 18668428 Review.
The UCSF-FDA TransPortal: a public drug transporter database.
Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, Giacomini KM. Morrissey KM, et al. Among authors: huang sm. Clin Pharmacol Ther. 2012 Nov;92(5):545-6. doi: 10.1038/clpt.2012.44. Clin Pharmacol Ther. 2012. PMID: 23085876 Free PMC article.
Therapeutic protein-drug interactions and implications for drug development.
Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, Lesko LJ. Huang SM, et al. Clin Pharmacol Ther. 2010 Apr;87(4):497-503. doi: 10.1038/clpt.2009.308. Epub 2010 Mar 3. Clin Pharmacol Ther. 2010. PMID: 20200513
When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. Huang SM, et al. Clin Pharmacol Ther. 2009 Nov;86(5):475-9. doi: 10.1038/clpt.2009.190. Clin Pharmacol Ther. 2009. PMID: 19844224
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Among authors: huang sm. Clin Pharmacol Ther. 2001 Aug;70(2):103-14. doi: 10.1067/mcp.2001.116891. Clin Pharmacol Ther. 2001. PMID: 11503003 No abstract available.
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Among authors: huang sm. Br J Clin Pharmacol. 2001 Jul;52(1):107-17. doi: 10.1046/j.0306-5251.2001.temp.1441.x. Br J Clin Pharmacol. 2001. PMID: 11453898 Free PMC article. Review. No abstract available.
EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences.
Tucker GT, Houston JB, Huang SM. Tucker GT, et al. Among authors: huang sm. Eur J Pharm Sci. 2001 Jul;13(4):417-28. doi: 10.1016/s0928-0987(01)00148-8. Eur J Pharm Sci. 2001. PMID: 11480400 No abstract available.
998 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback